Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

Development and Validation of an LC-MS Assay for Finasteride and its Application to Prostate Cancer Prevention Trial Sample Analysis

(2013) X. Chen et al.   JOURNAL OF CHROMATOGRAPHIC SCIENCE

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

(2011) Jesus Garcia-Donas et al.   LANCET ONCOLOGY

Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients

(2011) Masatomo Miura et al.   PHARMACOGENOMICS

A Functional Polymorphism in the CYP3A4 Gene is Associated with Increased Risk of Coronary Heart Disease in the Chinese Han Population

(2010) Bao-xia He et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients

(2010) M Onizuka et al.   BONE MARROW TRANSPLANTATION

Finasteride

(2010) Uzair B Chaudhary et al.   Expert Opinion on Drug Metabolism & Toxicology

Alcohol consumption, finasteride, and prostate cancer risk

(2009) Zhihong Gong et al.   CANCER

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

(2009) D. H. Kim et al.   CLINICAL CANCER RESEARCH

CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

(2008) Yuan Gao et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY